Evidence map›Paper›PMID 25596326›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2015

Multivalent display of pendant pro-apoptotic peptides increases cytotoxic activity.

David S H Chu, Michael J Bocek, Julie Shi, Anh Ta, Chayanon Ngambenjawong, Robert C Rostomily, Suzie H Pun

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Molecular targeted treatment and drug delivery system for gastric cancer.Journal of cancer research and clinical oncology · 2021
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.Journal of controlled release : official journal of the Controlled Release Society · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

David S H ChuDepartment of Bioengineering and Molecular Engineering and Sciences Institute, University of Washington, Seattle, WA 98195, USA.
Michael J BocekDepartment of Bioengineering and Molecular Engineering and Sciences Institute, University of Washington, Seattle, WA 98195, USA.
Julie ShiDepartment of Bioengineering and Molecular Engineering and Sciences Institute, University of Washington, Seattle, WA 98195, USA.
Anh TaDepartment of Bioengineering and Molecular Engineering and Sciences Institute, University of Washington, Seattle, WA 98195, USA.
Chayanon NgambenjawongDepartment of Bioengineering and Molecular Engineering and Sciences Institute, University of Washington, Seattle, WA 98195, USA.
Robert C RostomilyDepartment of Neurological Surgery, University of Washington, Seattle, WA 98195, USA.
Suzie H PunDepartment of Bioengineering and Molecular Engineering and Sciences Institute, University of Washington, Seattle, WA 98195, USA. Electronic address: spun@uw.edu.
University of Washington · US

Funding

POTENTIATING BREAST CANCER THERAPIES BY TARGETING TUMOR-ASSOCIATED MACROPHAGER01CA177272 · NCI · UNIVERSITY OF WASHINGTON · PI PUN, SUZIE H. · 2014 to 2019
$2.0M
Nanotechnology and Physical Science Training Program in Cancer ResearchT32CA138312 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2009 to 2013
$1.5M
NCI NIH HHS 1R01CA177272NCI NIH HHS CA138312NCI NIH HHS R01 CA177272NCI NIH HHS T32 CA138312
6 · The paper itself

Abstract

Several cationic antimicrobial peptides have been investigated as potential anti-cancer drugs due to their demonstrated selective toxicity towards cancer cells relative to normal cells. For example, intracellular delivery of KLA, a pro-apoptotic peptide, results in toxicity against a variety of cancer cell lines; however, the relatively low activity and small size lead to rapid renal excretion when applied in vivo, limiting its therapeutic potential. In this work, apoptotic peptide-polymer hybrid materials were developed to increase apoptotic peptide activity via multivalent display. Multivalent peptide materials were prepared with comb-like structure by RAFT copolymerization of peptide macromonomers with N-(2-hydroxypropyl) methacrylamide (HPMA). Polymers displayed a GKRK peptide sequence for targeting p32, a protein often overexpressed on the surface of cancer cells, either fused with or as a comonomer to a KLA macromonomer. In three tested cancer cell lines, apoptotic polymers were significantly more cytotoxic than free peptides as evidenced by an order of magnitude decrease in IC50 values for the polymers compared to free peptide. The uptake efficiency and intracellular trafficking of one polymer construct was determined by radiolabeling and subcellular fractionation. Despite their more potent cytotoxic profile, polymeric KLA constructs have poor cellular uptake efficiency (<1%). A significant fraction (20%) of internalized constructs localize with intact mitochondrial fractions. In an effort to increase cellular uptake, polymer amines were converted to guanidines by reaction with O-methylisourea. Guanidinylated polymers disrupted function of isolated mitochondria more than their lysine-based analogs, but overall toxicity was decreased, likely due to inefficient mitochondrial trafficking. Thus, while multivalent KLA polymers are more potent than KLA peptides, these materials can be substantially improved by designing next generation materials with improved cellular internalization and mitochondrial targeting efficiency.

Indexed as

Drug CarriersAnimalsAntineoplastic AgentsApoptosisCarrier ProteinsCell SurvivalChemistry, PharmaceuticalDose-Response Relationship, DrugHeLa CellsHumansInhibitory Concentration 50Intercellular Signaling Peptides and ProteinsLigandsMethacrylatesMiceMitochondrial ProteinsAntineoplastic AgentsC1QBP protein, humanCarrier ProteinsDrug Carriershydroxypropyl methacrylateIntercellular Signaling Peptides and ProteinsKLA peptideLigandsMethacrylatesMitochondrial ProteinsOligopeptidesPeptidesApoptotic peptidesMultivalencyPeptide deliveryRAFT polymerization

Identifiers

PMID25596326
PMCPMC4395534
OpenAlexW2059624781

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.